Phaseline

Companies › Hemerion Therapeutics

Hemerion Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
5-ALA HCl intraoperative Photodynamic Therapy (PDT)
Photodynamic therapy using 5-aminolevulinic acid as a photosensitizer
PPOXPhase 1Primary Glioblastoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT057364065-ALA HCl intraoperative Photodynamic Therapy (PDT)Phase 1Primary GlioblastomaOncologyMar 2026

Targets

PPOX (1)

Companies with the same targets

Sun Pharmaceutical Industries Lee's Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.